Fig. 1 · Structure

Documents & Downloads

Decitabine

Cat. No. A10292 CAS 2353-33-5

DNA Methyltransferase Inhibitors

Decitabine is a hypomethylating agent.It hypomethylates DNA by inhibiting DNA methyltransferase.

In Stock

Publications for Decitabine

6 publications citing this product

  1. Jiawei Du, .et al. , Neural Regeneration Research, 2026, April 14 PMID: 41975603
  2. Tianxing Ying, .et al. , Cancers (Basel), 2022, Dec 30;15(1):243 PMID: 36612238
  3. Borbala Szabo, .et al. , J Clin Endocrinol Metab, 2022, Sep 5;dgac496 PMID: 36059148
  4. Sangni Qian, .et al. , Clin Epigenetics, 2022, Sep 5;14(1):111 PMID: 36064442
  5. Borbála Szabó, .et al. , J Clin Endocrinol Metab, 2020, Jun 1;105(6):dgaa156 PMID: 32232382
  6. Bracha Shraibman, .et al. , Mol Cell Proteomics, 2016, Sep; 15(9): 3058-3070 PMID: 27412690

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

In HCT116 cells, decitabine reduced DNMT1 protein after 48 h. DNMT1-deficient cells were less responsive in a 96 h viability assay, supporting a role for DNMT1 status in cellular response; the deficient model retained low DNMT1 protein. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
DNA methylation (HL-60, KG1a cells)

In Vitro Studies

Decitabine had a reported 96 h MTT IC50 of 0.48 µM in HCT116 DNMT1+/+ cells, versus >10 µM in the DNMT1-deficient counterpart. These are model-specific viability endpoints. [1]

In RKO cells, 24 h decitabine exposure increased MEF2C-AS1 RNA at 15 and 20 µM versus 0 µM; 10 µM was nonsignificant. Separate gene-overexpression assays do not demonstrate drug-induced inhibition of proliferation or migration. [2]

DNMT1 depletion and genotype-dependent decitabine response in HCT116 cells

Cell-based study · HCT116 DNMT1+/+ and isogenic DNMT1-deficient (DNMT1-Δexons3-5/Δexons3-5) colorectal cancer cells [1]

The DNMT1-deficient counterpart was less responsive to decitabine in the 96 h MTT assay. The deficient cells retained low DNMT1 protein; these data should not be interpreted as a complete protein-null system.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
HCT116 cell viability after 96 hIC50 DNMT1+/+: 0.48 µM; DNMT1-deficient: >10 µM[1]
DNMT1 protein abundanceQualitative immunoblot response Decitabine reduced DNMT1 protein after 48 h in DNMT1+/+ cells; low residual DNMT1 was detected in the deficient line.[1]

Literature-Reported Treatment Conditions

Treatment concentration
Western blot: 0, 0.05, 0.5 and 5 µM; MTT: increasing concentrations (Figure 1c).
Exposure duration
48 h for DNMT1 protein; 96 h for MTT viability.
Method
Cell exposure to decitabine; separate matched dose-response/protein readouts within the genotype-comparison study.
Co-treatment
Decitabine single-agent results; aza-T-dCyd and azacitidine are separate comparator compounds, not combinations.
Reported limits
Vehicle formulation is not specified in the selected methods. No Adooq SKU, lot or analytical stereochemical assay reported.
Methods and source locations

Compound reported in the paper: Decitabine; Compound label in the paper: DAC

Compound-level research evidence; does not validate A10292 or a particular Adooq lot.

Figure 1a-c; Results: Deletion or disruption of DNMT1 gene confers resistance to DNMTi; Methods: Cell lines and drugs, MTT assay, Western blotting

HCT116 cell viability after 96 h: MTT; triplicate samples, at least three independent experiments; Figure 1 caption reports mean ± SD. — Figure 1c and corresponding Results; Methods: MTT assay

DNMT1 protein abundance: DNMT1 Western blot with β-actin control; representative experiment from at least three independent experiments. — Figure 1a,b and caption; Methods: Western blotting

MEF2C-AS1 expression after decitabine exposure in RKO cells

Cell-based study · Human RKO colorectal cancer cells [2]

Decitabine increased MEF2C-AS1 RNA relative to the 0 µM group at 15 and 20 µM. The 10 µM comparison was nonsignificant. The separate plasmid-overexpression proliferation/migration experiments do not establish decitabine effects on those endpoints.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
MEF2C-AS1 RNA expressionqRT-PCR response 15 µM: **p<0.01; 20 µM: ***p<0.001; 10 µM: ns (p>0.05), versus 0 µM.[2]

Literature-Reported Treatment Conditions

Treatment concentration
0, 10, 15 and 20 µM
Exposure duration
24 h
Method
Exposure to 5-Aza-dC followed by qRT-PCR.
Co-treatment
Single-agent decitabine; no plasmid cotreatment in this adopted experiment.
Reported limits
Vehicle and replicate number were not identified in the selected assay methods/caption. No SKU, lot, purity or independent stereochemical analysis reported.
Methods and source locations

Compound reported in the paper: Decitabine; Compound label in the paper: 5-Aza-dC

Compound-level research evidence; does not validate A10292 or a particular Adooq lot.

Figure 7b and caption; Results: Influence of MEF2C-AS1 methylation on its expression in colorectal cancer cells; Methods: Cell culture and treatment, qRT-PCR, Statistical analysis

MEF2C-AS1 RNA expression: qRT-PCR with β-actin internal control; Figure 7b displays relative expression as 2^-ΔΔCT. Exact fold changes are not inferred from bars; replicate n is not specified in the selected caption/methods. — Figure 7b and caption; corresponding Results; Cell culture and treatment

In Vivo Studies

In HCT116 xenograft-bearing mice, decitabine (0.75 mg/kg intraperitoneally, using an intermittent daily schedule) delayed tumor growth relative to saline and reduced tumor DNMT1. The decitabine p21 comparison was nonsignificant in Figure 4c. [1]

Decitabine response in HCT116 xenografts

Animal study · Female athymic nude mice (nu/nu NCr) bearing HCT116 DNMT1+/+ xenografts [1]

Decitabine delayed xenograft growth relative to saline. The accompanying tissue analysis showed reduced DNMT1, while the decitabine p21 comparison was labeled nonsignificant.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Tumor growth relative to salineTumor growth delay Significant delay reported; maximal decitabine delay at day 12; saline n=16, DAC n=18.[1]
Tumor DNMT1 and p21Immunohistochemistry DNMT1: **P<0.01 versus saline; p21: ns versus saline. Caption describes 5 mouse tumor samples.[1]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Daily for 5 days, 2 days rest, daily for 5 days, then 9 days rest in each 21-day cycle.
Treatment course
2–3 cycles in shared methods; tumor tissue collected on day 11 of treatment cycles.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Decitabine versus saline
0.75 mg/kg
Saline-treated tumor-bearing miceTumor growth delay reported, maximal for decitabine at day 12. Tumor DNMT1 decreased; p21 comparison versus saline was nonsignificant in Figure 4c.[1]
Decitabine versus saline
Model: Female athymic nude mice (nu/nu NCr) bearing HCT116 DNMT1+/+ xenografts
Reported limits: Drug formulation and allocation/randomization/blinding details for this comparison were not identified in the selected methods. Figure 4a labels saline n=16 and DAC n=18; Figure 4c describes 5 tumor samples, without clarifying their relation to the growth cohort.
Methods and source locations

Compound reported in the paper: Decitabine; Compound label in the paper: DAC

Compound-level research evidence; does not validate A10292 or a particular Adooq lot.

Figure 4a-c and caption; Results: Tumor growth inhibition and modulation of DNMT1 and p21; Methods: In vivo treatment of xenograft and PDX tumors, and immunohistochemistry

Tumor growth relative to saline: Bidirectional caliper measurements; no exact magnitude inferred from the plotted bar. — Figure 4a and caption; corresponding Results

Tumor DNMT1 and p21: DNMT1 staining index; p21 percentage staining. Figure labels, rather than the broader prose, determine the p21 significance interpretation. — Figure 4b,c and caption

Decitabine versus saline · Figure 4a-c and caption; Results: Tumor growth inhibition and modulation of DNMT1 and p21; Methods: In vivo treatment of xenograft and PDX tumors, and immunohistochemistry

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 2353-33-5
Applications DNA Methyltransferase Inhibitors
Formula C8H12N4O4
Molecular Weight 228.2
Synonyms Dacogen; 5-Aza-dC
SMILES
C1[C@@H]([C@H](O[C@H]1N2C=NC(=NC2=O)N)CO)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 44 mg/mL (192.8 mM)
Water 10 mg/mL (43.81 mM)
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
9 mg/mL
Vehicle
water

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Angelo B. A. Laranjeira, Melinda G. Hollingshead, Dat Nguyen, et al. DNA damage, demethylation and anticancer activity of DNA methyltransferase (DNMT) inhibitors Scientific reports (2023). PMID: 37045940 DOI: 10.1038/s41598-023-32509-4 Source material
  2. [2] Sangni Qian, Shujuan Lin, Xin Xu, et al. Hypermethylation of tumor suppressor lncRNA MEF2C-AS1 frequently happened in patients at all stages of colorectal carcinogenesis Clinical epigenetics (2022). PMID: 36064442 DOI: 10.1186/s13148-022-01328-1 Source material

Publications

6 publications citing this product

  1. Jiawei Du, .et al. , Neural Regeneration Research, 2026, April 14 PMID: 41975603
  2. Tianxing Ying, .et al. , Cancers (Basel), 2022, Dec 30;15(1):243 PMID: 36612238
  3. Borbala Szabo, .et al. , J Clin Endocrinol Metab, 2022, Sep 5;dgac496 PMID: 36059148
  4. Sangni Qian, .et al. , Clin Epigenetics, 2022, Sep 5;14(1):111 PMID: 36064442
  5. Borbála Szabó, .et al. , J Clin Endocrinol Metab, 2020, Jun 1;105(6):dgaa156 PMID: 32232382
  6. Bracha Shraibman, .et al. , Mol Cell Proteomics, 2016, Sep; 15(9): 3058-3070 PMID: 27412690

Added to your cart

View Cart Checkout
Loading...